Low serum dehydroepiandrosterone levels are associated with diabetic retinopathy in patients with type 2 diabetes mellitus

Zhang, Xinxin; Huang, Yunbo; Xu, Ning; Feng, Wenli; Qiao, Jingting; Liu, Ming

doi:10.1111/jdi.13997

Cited by 6 publications

(4 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, DHEAS levels correlated inversely with the degree of urinary albumin excretion in T2DM male patients [191] and with the duration of diabetes [192]. Decreased DHEAS concentrations in T2DM patients were also associated with diabetic retinopathy [193], atherosclerosis [194,195], diabetic kidney disease [196], and coronary heart disease in diabetic men [197].…”

Section: Diabetes and Hormonesmentioning

confidence: 96%

Diabetes Mellitus Should Be Considered While Analysing Sarcopenia-Related Biomarkers

Rentflejsz,

Wojszel

2024

JCM

View full text Add to dashboard Cite

Sarcopenia is a chronic, progressive skeletal muscle disease characterised by low muscle strength and quantity or quality, leading to low physical performance. Patients with type 2 diabetes mellitus (T2DM) are more at risk of sarcopenia than euglycemic individuals. Because of several shared pathways between the two diseases, sarcopenia is also a risk factor for developing T2DM in older patients. Various biomarkers are under investigation as potentially valuable for sarcopenia diagnosis and treatment monitoring. Biomarkers related to sarcopenia can be divided into markers evaluating musculoskeletal status (biomarkers specific to muscle mass, markers of the neuromuscular junction, or myokines) and markers assuming causal factors (adipokines, hormones, and inflammatory markers). This paper reviews the current knowledge about how diabetes and T2DM complications affect potential sarcopenia biomarker concentrations. This review includes markers recently proposed by the expert group of the European Society for the Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) as those that may currently be useful in phase II and III clinical trials of sarcopenia: myostatin (MSTN); follistatin (FST); irisin; brain-derived neurotrophic factor (BDNF); procollagen type III N-terminal peptide (PIIINP; P3NP); sarcopenia index (serum creatinine to serum cystatin C ratio); adiponectin; leptin; insulin-like growth factor-1 (IGF-1); dehydroepiandrosterone sulphate (DHEAS); C-reactive protein (CRP); interleukin-6 (IL-6), and tumor necrosis factor α (TNF-α). A better understanding of factors influencing these biomarkers’ levels, including diabetes and diabetic complications, may lead to designing future studies and implementing results in clinical practice.

show abstract

Section: Diabetes and Hormonesmentioning

confidence: 96%

Diabetes Mellitus Should Be Considered While Analysing Sarcopenia-Related Biomarkers

Rentflejsz,

Wojszel

2024

JCM

View full text Add to dashboard Cite

show abstract

“…After the patients had fasted for at least 8 hours, venous blood samples were taken at 6 a.m. on the second day of admission. Our lab performed the steroid hormone assay as previously described (17)(18)(19).…”

Section: Study Participantsmentioning

confidence: 99%

Low serum dehydroepiandrosterone is associated with diabetic dyslipidemia risk in males with type 2 diabetes

Chen,

Li,

Zhang

et al. 2023

Front. Endocrinol.

Self Cite

View full text Add to dashboard Cite

ObjectiveSex steroid hormones are associated with the advancement of metabolic diseases such as dyslipidemia. This cross-sectional study aimed to investigate the relationship between dehydroepiandrosterone, dehydroepiandrosterone sulfate, androstenedione, and testosterone levels and the risk of dyslipidemia in people with type 2 diabetes mellitus.Materials and MethodsThe analysis included 1,927 patients with type 2 diabetes mellitus. Serum dehydroepiandrosterone, dehydroepiandrosterone sulfate, androstenedione, and testosterone levels were determined using lipid chromatography-tandem mass spectrometry. Multivariable analyses were performed to investigate the association between the variables and dyslipidemia.ResultsThe multivariable-adjusted odds ratio (OR) and 95% confidence interval (CI) of dyslipidemia across DHEA tertiles were 0.39 and 0.24-0.64, respectively (p trend = 0.001). This relationship was still maintained when analyzed as a continuous variable (odds ratio, 0.96; 95% confidence interval, 0.92–0.99; P < 0.01). However, in males with type 2 diabetes mellitus, no significant correlations were found between rising levels of dehydroepiandrosterone sulfate, androstenedione, and total testosterone and the risk of dyslipidemia (all P > 0.05). Furthermore, there was no significant association between androgen precursors and total testosterone with regard to the risk of developing dyslipidemia (all P > 0.05).ConclusionsSerum dehydroepiandrosterone levels were substantially and adversely correlated with dyslipidemia in adult men with T2DM. These results indicated that dehydroepiandrosterone may have an essential role in the development of dyslipidemia. More prospective research is required to validate this link.

show abstract

“…In China, the prevalence of DR among diabetic individuals exhibits considerable variation, with estimates ranging from 18.45% to 31.8%. This variation may reflect differences in study methodologies or demographic variations across regions, highlighting the complexity of managing DR within diverse populations ( 6 , 7 ). Despite advancements in the understanding of DR, significant challenges in its early diagnosis and treatment remain ( 8 , 9 ).…”

Section: Introductionmentioning

confidence: 99%

Association between AST/ALT ratio and diabetic retinopathy risk in type 2 diabetes: a cross-sectional investigation

Li,

Hao,

Lin

et al. 2024

Front. Endocrinol.

View full text Add to dashboard Cite

ObjectiveThis study aimed to explore the association between the aspartate aminotransferase to alanine aminotransferase ratio (AST/ALT ratio) and diabetic retinopathy (DR) in patients with type 2 diabetes.MethodsIn this cross-sectional study, clinical data from 3002 patients with type 2 diabetes admitted to the Department of Endocrinology of our hospital between January 1, 2021, and December 1, 2022, were retrospectively collected. Measurements of AST and ALT were conducted and diabetes-related complications were screened. The association between AST/ALT ratio and diabetic retinopathy was assessed using multivariate logistic regression, and a generalized additive model (GAM) was used to investigate nonlinear relationships. Subgroup analyses and interaction tests were also conducted.ResultsAmong the 3002 patients, 1590 (52.96%) were male and 1412 (47.04%) were female. The mean AST/ALT ratio was 0.98 ± 0.32, ranging from 0.37 (Min) to 2.17 (Max). Diabetic retinopathy was present in 40.47% of the patients. After multivariate adjustments, for each 0.1 unit increase in AST/ALT ratio, the risk of DR increased by 4% (OR = 1.04, 95% CI: 1.01–1.07, p=0.0053). Higher AST/ALT ratio quartiles were associated with Higher prevalence of DR (OR vs. Q1: Q4 = 1.34 (CI: 1.03–1.75, p=0.0303).The GAM and smoothed curve fit indicated a linear relationship between AST/ALT ratio and DR risk, with no significant interaction effects across different subgroups.ConclusionOur study demonstrates a positive correlation between the AST/ALT ratio and diabetic retinopathy risk in type 2 diabetes, suggesting its potential role in assessing DR risk.

show abstract

Low serum dehydroepiandrosterone levels are associated with diabetic retinopathy in patients with type 2 diabetes mellitus

Cited by 6 publications

References 60 publications

Diabetes Mellitus Should Be Considered While Analysing Sarcopenia-Related Biomarkers

Diabetes Mellitus Should Be Considered While Analysing Sarcopenia-Related Biomarkers

Low serum dehydroepiandrosterone is associated with diabetic dyslipidemia risk in males with type 2 diabetes

Association between AST/ALT ratio and diabetic retinopathy risk in type 2 diabetes: a cross-sectional investigation

Contact Info

Product

Resources

About